FindTrial
Sign In

Study of immunohistochemical expression of tumor supressor gene p53 in carcinoma cervix.

To study clinco-pathological parameters of malignant lesions of cervix for FIGO and TNM staging and the nature of immunohistochemical expression of P53 in various types of carcinoma cervix. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/03/106962
Enrollment
45
Registered
2026-03-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

Intervention1: Nil: Nil Control Intervention1: NIL: Nil

Sponsors

Datta Meghe Institute of Higher Education and Research (DMIHER)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All cases clinically diagnosed as Carcinoma Cervix. 2. All cases diagnosed as Carcinoma Cervix on histopathology. 3. Colposcopy guided biopsy specimens, Hysteroscopy guided biopsy specimen, Cone biopsy specimens received in the dept of pathology. 4. Primary cases of carcinoma cervix without any history of previous treatment.

Exclusion criteria

Exclusion criteria: 1. Male patients. 2. Female patients under 15 years of age. 3. Already treated cases of carcinoma cervix. 4. All the benign cases of cervix. 5. Patients not opting for consent or withdrawal of consent.

Design outcomes

Primary

MeasureTime frame
Immunohistochemical expression of tumor supressor gene P53 in carcinoma cervix. Timepoint: 8 weeks—

Secondary

MeasureTime frame
NILTimepoint: Nil—

Countries

India

Contacts

Public ContactAnil Agrawal

Datta Meghe Institute of Higher Education and Research (DMIHER)

dranilagrawal.456@gmail.com9850309278

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026